Florenzo Iannone1, Giorgio Carlino2, Antonio Marchesoni3, Piercarlo Sarzi-Puttini4, Roberto Gorla5, Giovanni Lapadula6. 1. Rheumatology unit, university of Bari, Policlinico, Piazza G. Cesare 11, 70124 Bari, Italy. Electronic address: florenzo.iannone@uniba.it. 2. Rheumatology service DSS Casarano Gallipoli, ASL Lecce, Italy. 3. Rheumatology unit, Ospedale G Pini, Milano, Italy. 4. Rheumatology unit, Ospedale Sacco, Milano, Italy. 5. Rheumatology unit, university of Brescia, Brescia, Italy. 6. Rheumatology unit, university of Bari, Policlinico, Piazza G. Cesare 11, 70124 Bari, Italy.
Abstract
OBJECTIVES: The aim of this study was to assess whether good EULAR response assessed at 3months may predict the achievement of low disease activity (LDA) at 1year in rheumatoid arthritis (RA) patients on treatment with certolizumab pegol (CZP). METHODS: From the nationwide Italian registry, we analysed 278 RA patients (age 54.8±12years, duration of disease 9.8±8years, female 84%) initiating CZP as first line (68%) or≥second line (32%) of biological treatment because of their active disease. Assessment of disease activity was based on 28 joint Disease Activity Score (DAS28). A reduction of DAS28>1.2 (good EULAR response) was assessed at 3months, and the achievement of LDA (DAS28≤3.2) was evaluated at 1year. Multiple regression models were used to estimate predictors of early good EULAR response or LDA. RESULTS: The percentages of patients attaining good EULAR response were 52% at 3, 65% at 6, and 66% at 12months. Furthermore, 51.2% (98/192) of the patients reached LDA at 12months. Patients taking CZP as first biological treatment had adjusted odds ratios (OR) of good EULAR response at 3months 6 folds higher than in those with≥1 prior biological drug (OR 6.7, 95% CI 1.97-23.1). While, the strongest variable correlating with 12months LDA was the achievement of good EULAR response at 3months (OR 11.3, 95% CI 13.1-34.8). CONCLUSIONS: Our findings showed that attaining good EULAR response at 3months strongly predicted 1year LDA in RA patients treated with CZP in real-life settings.
OBJECTIVES: The aim of this study was to assess whether good EULAR response assessed at 3months may predict the achievement of low disease activity (LDA) at 1year in rheumatoid arthritis (RA) patients on treatment with certolizumab pegol (CZP). METHODS: From the nationwide Italian registry, we analysed 278 RApatients (age 54.8±12years, duration of disease 9.8±8years, female 84%) initiating CZP as first line (68%) or≥second line (32%) of biological treatment because of their active disease. Assessment of disease activity was based on 28 joint Disease Activity Score (DAS28). A reduction of DAS28>1.2 (good EULAR response) was assessed at 3months, and the achievement of LDA (DAS28≤3.2) was evaluated at 1year. Multiple regression models were used to estimate predictors of early good EULAR response or LDA. RESULTS: The percentages of patients attaining good EULAR response were 52% at 3, 65% at 6, and 66% at 12months. Furthermore, 51.2% (98/192) of the patients reached LDA at 12months. Patients taking CZP as first biological treatment had adjusted odds ratios (OR) of good EULAR response at 3months 6 folds higher than in those with≥1 prior biological drug (OR 6.7, 95% CI 1.97-23.1). While, the strongest variable correlating with 12months LDA was the achievement of good EULAR response at 3months (OR 11.3, 95% CI 13.1-34.8). CONCLUSIONS: Our findings showed that attaining good EULAR response at 3months strongly predicted 1year LDA in RApatients treated with CZP in real-life settings.
Authors: Alain Saraux; René-Marc Flipo; Francis Fagnani; Jacques Massol; Gabrielle Cukierman; Jean-Michel Joubert; Philippe Huot-Marchand; Bernard Combe Journal: RMD Open Date: 2020-01